Home/Pipeline/Velsipity

Velsipity

Ulcerative Colitis

ApprovedActive

Key Facts

Indication

Ulcerative Colitis

Phase

Approved

Status

Active

Company

Pfizer

About Pfizer

Pfizer's mission is to deliver 'Breakthroughs that change patients' lives' through scientific innovation across a diversified portfolio of therapeutics and vaccines. Its strategic achievements include the rapid development and global commercialization of the COVID-19 vaccine Comirnaty, establishing a leading mRNA platform, and a disciplined pipeline expansion into high-growth areas like obesity and oncology. The company's strategy focuses on sharpening its R&D focus on transformative science, optimizing its cost structure, and deploying capital for strategic business development to drive long-term growth post-pandemic.

View full company profile

Therapeutic Areas

Internal Medicine Oncology Vaccines Inflammation & Immunology Rare Disease

Other Ulcerative Colitis Drugs

Drug	Company	Phase	Status
PALI-2108	Palisade Bio	Phase 2	Advancing towards initiation
ALTB-268	AltruBio	Phase IIa	Active
AIM-HI-UC	PathAI	Clinical Trials	Active
Patient Stratification in Ulcerative Colitis	Enable Medicine	Research	Active
Mesalazine (Lifecycle Management)	Dr. Falk Pharma	Approved/Phase 3	Active
AhR Agonist Program	Azora Therapeutics	Phase 1b	Active
R-3750	Virtici	Phase 1	Active
GPR35 Inhibitor	ThirtyFiveBio	Preclinical	Active
BEN-8744	BenevolentAI	Phase 1b	Active
BT-600	Biora Therapeutics	Phase 1	Active
Asacol® (mesalazine)	Tillotts Pharma	Approved	Active
MB310	Microbiotica	Phase 1b	Active